SCHEMBL15720111

SCHEMBL15720111

CN(C)CCn1cc(-c2cccc(Cl)c2)nc1C1CCNCC1

nearest known ligand 0.46

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 17/20 0.46
AKT1 P31749 17/20 0.46
RPS6KA1 Q15418 1/20 0.43
TLR8 Q9NR97 1/20 0.43
AKT2 P31751 4/20 0.42
KCNH2 Q12809 4/20 0.42
AKT3 Q9Y243 4/20 0.42
RAD52 P43351 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11903905 0.99 RPS6KB1 (0.46) RPS6KB1AKT1RPS6KA1TLR8AKT2
SCHEMBL15720179 0.88 GABRA1 (0.44) RPS6KB1AKT1RPS6KA1TLR8AKT2
SCHEMBL15719892 0.87 RPS6KB1 (0.41) RPS6KB1AKT1RPS6KA1AKT2KCNH2
Hydrochloric Acid SCHEMBL2063000 0.86 RPS6KB1 (0.43) RPS6KB1AKT1RPS6KA1TLR8AKT2
Hydrochloric Acid SCHEMBL11904052 0.86 RPS6KB1 (0.41) RPS6KB1AKT1RPS6KA1TLR8AKT2
SCHEMBL2063263 0.86 RPS6KB1 (0.50) RPS6KB1AKT1RPS6KA1AKT2KCNH2
SCHEMBL15720450 0.86 HTR2C (0.46) RPS6KB1AKT1RPS6KA1TLR8AKT2
Triaziquone SCHEMBL11903903 0.85 RPS6KA1 (0.41) RPS6KB1AKT1RPS6KA1AKT2KCNH2
Hydrochloric Acid SCHEMBL2062890 0.85 RPS6KB1 (0.49) RPS6KB1AKT1RPS6KA1AKT2KCNH2
SCHEMBL15720535 0.84 RPS6KB1 (0.52) RPS6KB1AKT1RPS6KA1AKT2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3299362-B1 IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY MERCK PATENT GMBH (DE) 2020-04-22 EP disclosed
EP-3299362-A1 IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY Merck Patent GmbH (DE) 2018-03-28 EP disclosed
US-9315517-B2 Imidazol-piperidinyl derivatives as modulators of kinase activity MERCK PATENT GMBH (DE) 2016-04-19 US disclosed
EP-2920154-A1 NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY Merck Patent GmbH (DE) 2015-09-23 EP disclosed
US-20150239902-A1 Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity MERCK PATENT GMBH (DE) 2015-08-27 US disclosed
WO-2014078634-A1 NOVEL IMIDAZOL-PIPERIDINYL DERIVATIVES AS MODULATORS OF KINASE ACTIVITY MERCK PATENT GMBH (DE) 2014-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239902-A1 Novel Imidazol-piperidinyl Derivatives as Modulators of Kinase Activity MAP4K2, MAP4K3, MAP3K4 RPS6KB1 318/4885AKT1 197/4885RPS6KA1 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.